NCT00251355已完成1 期
A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 3
- 主要终点
- To assess the maximum tolerated dose of weekly gemcitabine when administered with continuous infusion 5-fluorouracil and external beam radiation.
研究概览
简要总结
The purpose of this study is to test a new treatment of pancreatic cancer that cannot be removed by surgery. This treatment is a Phase I dose escalation research study which will combine one drug at increasing doses with a fixed dose of a second drug and radiation therapy. The drug that will be used at increasing doses is gemcitabine whereas 5-fluorouracil will remain the same for all patients.
详细描述
- Ultimately we plan to find the maximum tolerated dose of the combination of gemcitabine, 5-fluorouracil and radiation therapy. We also hope to assess the number of people who respond to this therapy and to assess the feasibility of giving intraoperative radiation therapy following gemcitabine, 5-fluorouracil, and external beam radiation therapy.
- A surgical procedure, either laparotomy or laparoscopy, will be required to check the amount of disease before treatment is started.
- All patients will receive the same two chemotherapy drugs and radiation therapy. Both gemcitabine and 5-fluorouracil will begin on the first week of radiation therapy. 5-fluorouracil will be given continuously by intravenous infusion and will continue until the external beam radiation therapy is completed. The gemcitabine will be given (at different doses for each cohort of patients) once per week for seven weeks. Radiation therapy will be given daily for five days for seven weeks. On those days when gemcitabine is given, radiation therapy will be given approximately four hours after the gemcitabine dose.
- Four weeks after completing the radiation therapy and chemotherapy, patients will undergo a scan to check the extent of disease. Following the scan, patients will be considered for a repeat surgical procedure to remove the tumor, if possible. If removal of the tumor is not possible, patients will receive intraoperative radiation therapy.
- After completing the therapy, patients will be seen at least every 3 months for one year. A complete physical exam and CT scan will be done regularly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 72 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic confirmation of locally unresectable pancreatic adenocarcinoma. Patients with either measurable of evaluable disease are eligible.
- •Unresectable, non-metastatic tumors. Unresectable patients include those with local extension of the tumor into adjacent structures and/or nodal metastasis.
- •Total bilirubin < 2.0 mg/dl
- •AST < 3x ULN
- •Serum creatinine < 2.0 mg/dl
- •WBC > 3,000/mm3
- •Platelets > 100,000/mm3
- •ECOG performance status < or = to 2
- •Life expectancy of greater than 12 weeks
排除标准
- •Evidence of peritoneal seeding by malignancy
- •Prior radiation therapy or chemotherapy for pancreatic cancer
- •Myocardial infarction in the past 6 months
- •Major surgery in past two weeks
- •Uncontrolled serious medical or psychiatric illness
- •Pregnant or lactating women
- •Concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
研究组 & 干预措施
5-FU/gemcitabine/RT
Experimental
干预措施: Gemcitabine (Drug)
5-FU/gemcitabine/RT
Experimental
干预措施: 5-Fluorouracil (Drug)
5-FU/gemcitabine/RT
Experimental
干预措施: Radiation Therapy (Procedure)
结局指标
主要结局
To assess the maximum tolerated dose of weekly gemcitabine when administered with continuous infusion 5-fluorouracil and external beam radiation.
时间窗: phase 1
次要结局
- To determine the safety if this regimen(phase 1)
- to obtain a preliminary assessment of the efficacy of this regimen in this patient population.(phase 1)
研究者
Charles S. Fuchs, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic CancerPancreatic CancerNCT01051284Georgetown University14
已完成
1 期
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the PancreasPancreatic CancerNCT01128296Amer Zureikat35
已完成
2 期
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary CancersBiliary CancerPancreatic CancerNCT01661114University of Michigan Rogel Cancer Center39
已完成
1 期
Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic CancerPancreatic CancerNCT00260364Royal Marsden NHS Foundation Trust44
已完成
2 期
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic CancerPancreatic CancerNCT00733850KangLaiTe USA85